Abstract
When deciding upon the optimal antifungal agent for treating onychomycosis, the safety profile of the available agents is an important consideration. The topical antifungal agents have adverse events that are localized to the application site, and these are generally not as significant as the adverse effects that may occur with oral agents. The drug of choice is the most cost-effective antimycotic with an acceptable adverse-events profile.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Gupta AK, Sauder DN, Shear NH (1994) Antifungal agents: an overview. Part I. J Am Acad Dermatol 30:677–698
Sherertz EF (1990) Are laboratory studies necessary for griseofulvin therapy? J Am Acad Dermatol 22:1103
Jones HE (1982) Ketoconazole. Arch Dermatol 118:217–219
Knight TE, Shikuma CY, Knight J (1991) Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 25:398–400
Gupta AK, Sauder DN, Shear NH (1994) Antifungal agents: an overview. Part II. J Am Acad Dermatol 30:911–933
Pittrof F, Gerhards J, Erni W et al (1992) Loceryl nail lacquer—realization of a new galenical approach to onychomycosis therapy. Clin Exp Dermatol 17[Suppl l]:26–28
Baran R (1993) Amorolfine nail lacquer: a new transungual delivery system for nail mycoses. JAMA [Southeast Asia Supplement] 9:5–6
Rigopoulos D, Katsambas A, Antoniou C et al (1996) Discoloration of the nail plate due to the misuse of amorolfine 5% nail lacquer. Acta Derm Venereol 76:83–84
Reinel D (1992) Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatology 184[Suppl l]:21–24
Salasche SJ (1990) Surgery. In: Scher RK, Daniel CR III (eds) Nails: therapy, diagnosis, surgery. Saunders, Philadelphia, pp 258–280
Haneke E, Baran R (1994) Nail surgery and traumatic abnormalities. In: Baran R, Dawber RPR (eds) Diseases of the nails and their management, 2nd edn. Blackwell Science Publications, Oxford, pp 345–416
Baran R, Hay RJ (1985) Partial surgical avulsion of the nail in onychomycosis. Clin Exp Dermatol 10:413–418
Cohen PR, Scher RK (1994) Topical and surgical treatment of onychomycosis. J Am Acad Dermatol 31:S74–77
Farber EM, South DA (1994) Urea ointment in the nonsurgical avulsion of nail dystrophies. Cutis 22:689–692
South DA, Farber EM (1980) Urea ointment in the nonsurgical avulsion of nail dystrophies—a reappraisal. Cutis 25:609–612
Buselmeier TJ (1980) Combination urea and salicylic acid ointment nail avulsion in nondystrophic nails: a follow-up observation. Cutis 25:397–405
Hay RJ, Roberts DT, Doherty VR et al (1988) The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin Exp Dermatol 13:164–167
Bonifaz A, Guzman A, Garcia C et al (1995) Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis. Int J Dermatol 34:500–501
Fritsch H (1992) Ultrastructural changes in onychomycosis during the treatment with bifonazole/urea ointment. Dermatology 185:32–36
Ishii M, Hamada T, Asai Y (1983) Treatment of onychomycosis by ODT therapy with 20% urea ointment and 2% tolnaftate ointment. Dermatologica 167:273–279
White MI, Clayton YM (1982) The treatment of fungus and yeast infections of nails by the method of chemical removal. Clin Exp Dermatol 7:273–276
Rollman O, Johansson S (1987) Hendersonula toruloidea infection: successful response of onychomycosis to nail avulsion and topical ciclopiroxolamine. Acta Derm Venereol 67:506–510
Leshin B, Whitaker DC (1988) Carbon dioxide laser matricectomy. J Dermatol Surg Oncol 14:608–611
Scher RK (1981) Surgical avulsion of nail plates by a proximal to distal technique. J Dermatol Surg Oncol 7:296–297
Rothermel E, Apfelberg DB (1987) Carbon dioxide laser use for certain diseases of the toenails. Clin Podiatr Med Surg 4:809–821
Geronemus RG (1992) Laser surgery of the nail unit. J Dermatol Surg Oncol 18:735–743
Apfelberg DB, Rothermel E, Eidtfeldt A et al (1984) Preliminary report on use of carbon dioxide laser in podiatry. J Am Podiatr Med Assoc 74:509–513
Gupta AK, De Doncker P, Scher RK et al (1997) Itraconazole for the treatment of onychomycosis: an overview. Dermatologic Clinics 15:121–135
Shear NH, Gupta AK (1995) Terbinafme for the treatment of pedal onychomycosis: a foot closer to the promised land of cured nails? Arch Dermatol 131:937–942
Sandoz Inc. (1995) Terbinafine product monograph. Sandoz Inc., Dorval, Québec
Sandoz Inc. (1996) Terbinafine product monograph. Sandoz Inc., New Jersey, USA
Pfizer Inc. (1994) Fluconazole product monograph. Pfizer Inc., Kirkland, Québec
Hay RJ (1993) Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 29:S50–S54
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Gupta, A.K. (1999). The Safety Aspects of Systemic and Topical Antifungal Agents Used in the Management of Onychomycosis. In: Shuster, S. (eds) Hydroxy-Pyridones as Antifungal Agents with Special Emphasis on Onychomycosis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58401-5_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-58401-5_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-65494-0
Online ISBN: 978-3-642-58401-5
eBook Packages: Springer Book Archive